For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.